GSK plc (LON/NYSE:GSK) has confirmed it has reached a confidential settlement with David Browne, resolving the case he filed in California state court. This case was set to go to trial on 20 February 2024, and instead will now be dismissed.
The settlement reflects the Company’s desire to avoid the distraction related to protracted litigation in this case.
GSK does not admit any liability in this settlement and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases.
